SCHEMBL1482170

SCHEMBL1482170

CCn1cc(-c2ccc(Cl)cc2Cl)nc1C=Cc1ccc(O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
LMNA P02545 1/20 0.40
PTGS1 P23219 2/20 0.39
PTGS2 P35354 2/20 0.39
GFER P55789 1/20 0.38
AR P10275 1/20 0.36
DPP4 P27487 2/20 0.35
DPP8 Q6V1X1 2/20 0.35
ALPL P05186 2/20 0.35
CA12 O43570 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
KDM4E B2RXH2 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
BACE1 P56817 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1482165 1.00 MAPT (0.42) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL1480642 0.97 MEN1 (0.45) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL1480644 0.97 MEN1 (0.45) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL1481820 0.91 LMNA (0.37) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL1481818 0.91 LMNA (0.37) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL1480339 0.89 LMNA (0.40) MAPTLMNADPP4DPP8ALPL
SCHEMBL1480335 0.89 LMNA (0.40) MAPTLMNADPP4DPP8ALPL
SCHEMBL1484093 0.88 MEN1 (0.41) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL1484091 0.88 MEN1 (0.41) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL1480782 0.87 RELA (0.42) MAPTSMN1; SMN2LMNADPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885MEN1 3467/4885KMT2A 1996/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885MEN1 3467/4885KMT2A 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.